[ad_1] Early last week, AbbVie was on every healthcare investment banker’s list. But with two quick deal announcements under its belt in just six days, AbbVie may have transformed its…
Tag: ROG.EB
This $5 Billion Biotech Home Run Took Less Than a Year
[ad_1] You can’t completely blame Pfizer’s executives, yet Roche’s $7 billion acquisition of a bowel-disease treatment that it owned until last year isn’t a great look. In a deal that…
Roche to Buy Bowel-Disease Drug From Roivant, Pfizer for More Than $7 Billion
[ad_1] Updated Oct. 23, 2023 6:55 am ET Roche Holding has agreed to buy the developer of a bowel-disease treatment from Roivant Sciences, a company started by Republican presidential candidate…
New Gene Therapy Could Face Uphill Battle Despite FDA Approval
[ad_1] The FDA approval of BioMarin’s gene therapy for hemophilia is a major win, but patient uptake could be slow. [ad_2] Source link
Regeneron Borrows From Big Pharma Playbook to Keep Roche, Shorts at Bay
[ad_1] Eylea, the company’s top-selling blockbuster, isn’t going away soon. [ad_2] Source link
Bayer to Replace CEO Werner Baumann With Former Roche Executive
[ad_1] Business New Chief Executive Bill Anderson will confront company’s legal troubles and its $43 billion in debt [ad_2] Source link